Evidence map›Paper›PMID 40236985›Full record

ArticleBioMedInformatics2023

OutSplice: A Novel Tool for the Identification of Tumor-Specific Alternative Splicing Events.

Joseph Bendik, Sandhya Kalavacherla, Nicholas Webster, Joseph Califano, Elana J Fertig, Michael F Ochs, Hannah Carter, Theresa Guo

Abstract read
In one paragraph

Article in BioMedInformatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Joseph BendikMoores Cancer Center, University of California San Diego, San Diego, CA 92037, USA.ORCID 0000-0003-0877-5639
Sandhya KalavacherlaMoores Cancer Center, University of California San Diego, San Diego, CA 92037, USA.
Nicholas WebsterMoores Cancer Center, University of California San Diego, San Diego, CA 92037, USA.
Joseph CalifanoMoores Cancer Center, University of California San Diego, San Diego, CA 92037, USA.
Elana J FertigQuantitative Sciences Division and Convergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21224, USA.
Michael F OchsDepartment of Mathematics and Statistics, The College of New Jersey, Ewing, NJ 08628, USA.
Hannah CarterMoores Cancer Center, University of California San Diego, San Diego, CA 92037, USA.ORCID 0000-0002-1729-2463
Theresa GuoMoores Cancer Center, University of California San Diego, San Diego, CA 92037, USA.ORCID 0000-0002-1689-3275

Funding

TR&D 3 - Network Guided Machine LearningP41GM103504 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BADER, GARY D. · 2012 to 2024
$17.3M
UC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4M
BLRD VA I01 BX000130BLRD VA I01 BX002709BLRD VA I01 BX004848BLRD VA IK6 BX005224NCATS NIH HHS KL2 TR001444NIGMS NIH HHS P41 GM103504
6 · The paper itself

Abstract

Protein variation that occurs during alternative splicing has been shown to play a major role in disease onset and oncogenesis. Due to this, we have developed OutSplice, a user-friendly algorithm to classify splicing outliers in tumor samples compared to a distribution of normal samples. Several tools have previously been developed to help uncover splicing events, each coming with varying methodologies, complexities, and features that can make it difficult for a new researcher to use or to determine which tool they should be using. Therefore, we benchmarked several algorithms to determine which may be best for a particular user's needs and demonstrate how OutSplice differs from these methodologies. We find that despite detecting a lower number of genes with significant aberrant events, OutSplice is able to identify those that are biologically impactful. Additionally, we identify 17 genes that contain significant splicing alterations in tumor tissue that were discovered across at least 5 of the tested algorithms, making them good candidates for future studies. Overall, researchers should consider a combined use of OutSplice with other splicing software to help provide additional validation for aberrant splicing events and to narrow down biologically relevant events.

Indexed as

algorithmalternative splicingbenchmarkinghead and neck cancersoftware

Identifiers

PMID40236985
PMCPMC11997874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.